News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

European Medicines Agency Accepts Marketing Authorization Application For Biovest International, Inc.’s Cancer Vaccine For Treatment Of Non-Hodgkin’s Follicular Lymphoma


1/13/2014 10:57:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MINNEAPOLIS & TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (“Biovest”), a leader and pioneer in the development of personalized cancer immunotherapies, today reported that the European Medicines Agency (EMA) accepted the Company’s Marketing Authorization Application (MAA) for BiovaxID™ (submitted to EMA as “Dasiprotimut-T Biovest”), a personalized cancer vaccine for the treatment of non-Hodgkin’s follicular lymphoma. The MAA validation confirms the submission is complete and begins the formal EMA review process intended to secure approval to market BiovaxID in the European Union and to allow prescription and sale of BiovaxID for the treatment of non-Hodgkin’s follicular lymphoma in patients who have achieved a first complete remission.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES